Welcome to our dedicated page for Tenaya Therapeutics SEC filings (Ticker: TNYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenaya Therapeutics filings document a clinical-stage biotechnology issuer focused on genetic and small-molecule approaches to heart disease. Recent 8-K reports furnish operating results and corporate updates tied to TN-201, TN-401 and TN-301, including clinical and regulatory disclosures for cardiomyopathy programs and research updates for cardiovascular target validation.
The company’s SEC record also includes definitive proxy materials for annual-meeting governance and shareholder voting matters, material-agreement disclosure for its cardiovascular target research collaboration, capital-structure information and Nasdaq continued-listing compliance disclosures. These filings frame Tenaya’s public reporting around pipeline development, financing capacity, governance and common stock status.
Tenaya Therapeutics director Williams R. Sanders received a grant of stock options for 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were awarded under the company’s 2021 Equity Incentive Plan. They vest in full on May 28, 2027, or earlier if the next annual stockholder meeting occurs before that date, provided Sanders continues as a service provider.
Tenaya Therapeutics director Jeffrey T. Walsh received a stock option grant covering 120,000 shares of common stock at an exercise price of $0.7989 per share. The option was granted under the company’s 2021 Equity Incentive Plan, vests in full on May 28, 2027 (or earlier, before the next annual stockholder meeting), and expires on May 27, 2036. This filing reports an award of options rather than any open-market share purchase or sale.
Tenaya Therapeutics, Inc. director Catherine Stehman-Breen received a grant of stock options covering 120,000 shares of common stock. These options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The option grant was made under the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan and will vest in full on May 28, 2027, or earlier on the day immediately before the next annual meeting of stockholders after the grant date, if that comes first, provided she continues as a service provider. The options expire on May 27, 2036, and following this grant she holds 120,000 options of this award.
Tenaya Therapeutics director Deepak Srivastava received a grant of stock options for 120,000 shares of common stock at an exercise price of $0.7989 per share. The options vest in full on May 28, 2027, or earlier immediately before the next annual stockholder meeting, if he continues as a service provider. The options expire on May 27, 2036.
Tenaya Therapeutics director Karah Herdman Parschauer received a stock option grant for 120,000 shares of common stock. The option has an exercise price of $0.7989 per share, expires on May 27, 2036, and will vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant, if she continues as a service provider.
Tenaya Therapeutics, Inc. director June Lee received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share and were granted as compensation, not through an open-market purchase.
The options will vest in full on May 28, 2027, or earlier on the day immediately before the next annual stockholder meeting after the grant date, as long as Lee continues as a service provider to the company. The options expire on May 27, 2036, and following this grant Lee holds 120,000 options in total.
Tenaya Therapeutics, Inc. reported that director Amy L. Burroughs received a grant of stock options covering 120,000 shares of common stock. The options have an exercise price of $0.7989 per share, were granted as compensation under the company’s Amended and Restated 2021 Equity Incentive Plan, and vest in full on May 28, 2027 or earlier, the day before the next annual stockholder meeting after the grant date, if sooner. The options expire on May 27, 2036, and this filing does not reflect any open‑market buying or selling of Tenaya shares.
Tenaya Therapeutics, Inc. amended and restated its 2021 Equity Incentive Plan after stockholder approval at the May 27, 2026 annual meeting. The plan now includes a one-time increase of approximately 3% of outstanding shares, adding 6,509,966 shares reserved for equity awards, and revises the annual evergreen provision to a 4% of outstanding shares formula without the prior 4 million share cap. Stockholders also elected three Class II directors to terms ending at the 2029 annual meeting and ratified Deloitte & Touche LLP as independent auditor for the 2026 fiscal year.
Tenaya Therapeutics Chief Executive Officer Ali Faraz reported an open-market sale of 3,390 shares of common stock at $0.7934 per share on May 18, 2026. According to the footnotes, the shares were sold to cover tax withholding obligations related to vesting restricted stock units awarded on February 6, 2025.
After this transaction, Faraz directly holds 440,014 shares of Tenaya Therapeutics common stock. The holding figure includes 321,581 shares that will be issued upon future vesting of restricted stock units, underscoring that the reported sale is tied to tax obligations rather than a reduction of long-term equity awards.
Tenaya Therapeutics Chief Medical Officer Tingley Whittemore reported a small share sale primarily tied to taxes. On the reported date, Whittemore sold 3,121 shares of common stock at $0.7936 per share to cover tax withholding obligations related to vesting restricted stock units awarded on January 24, 2025.
After this transaction, Whittemore held 215,497 shares of Tenaya Therapeutics common stock directly, which includes 112,919 shares that will be issued upon future vesting of restricted stock units. The filing reflects a routine, tax-driven disposition rather than a large change in overall ownership.